Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock.
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Tourmaline Bio, Inc. (NASDAQ: TRML) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $74.00 price target on the stock.
Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at Jefferies Financial Group Inc. from $41.00 to $72.00. They now have a "buy" rating on the stock.